CN Patent

CN114144414A — 固态形式

Assigned to Amgen Inc · Expires 2022-03-04 · 4y expired

What this patent protects

本披露提供了6‑氟‑7‑(2‑氟‑6‑羟基苯基)‑1‑(4‑甲基‑2‑(2‑丙烷基)‑3‑吡啶基)‑4‑((2S)‑2‑甲基‑4‑(2‑丙烯酰基)‑1‑哌嗪基)吡啶并[2,3‑d]嘧啶‑2(1H)‑酮的结晶形式和无定形形式，包括几种无水形式、水合物形式和溶剂化物形式，以及其固态形式；还提供了药物组合物和治疗由KRAS G12C抑制介导的疾病的方法。

USPTO Abstract

本披露提供了6‑氟‑7‑(2‑氟‑6‑羟基苯基)‑1‑(4‑甲基‑2‑(2‑丙烷基)‑3‑吡啶基)‑4‑((2S)‑2‑甲基‑4‑(2‑丙烯酰基)‑1‑哌嗪基)吡啶并[2,3‑d]嘧啶‑2(1H)‑酮的结晶形式和无定形形式，包括几种无水形式、水合物形式和溶剂化物形式，以及其固态形式；还提供了药物组合物和治疗由KRAS G12C抑制介导的疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114144414A
Jurisdiction
CN
Classification
—
Expires
2022-03-04
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.